Document is current
Any future updates will be listed below
-
Authors
De Ford, Christian
Guridi, Maitea
Chen, Yingjia
Murphy, Alexander P.
Wood, Claire
McMillan, Hugh J.
Mercuri, Eugenio
Crabtree, Nicola
Ward, Leanne
-
Funding
Funding for this research was provided by:
F. Hoffmann-La Roche
- License Information
-
More Information
Article History
Received: 15 October 2024
Accepted: 30 July 2025
First Online: 29 August 2025
Declarations
:
: For this type of study, formal consent is not required.
: CDF and MG are employees of F. Hoffmann-La Roche Ltd with potential stock options. APM is an employee of Roche Products Ltd with potential stock options. YC is an employee of Genentech with potential stock options. CW has provided a consultancy role to F. Hoffmann-La Roche Ltd, PTC Therapeutics, and Pfizer. HJM has provided a consultancy role to F. Hoffmann-La Roche Ltd, Novartis, Pfizer, Regenxbio and Solid Biosciences. HJM’s institution has received research funding from F. Hoffmann-La Roche Ltd, Novartis, Biogen, Dyne, PepGen, Sarepta, Italfarmaco, and Reveragen. EM has received fees from AveXis, Biogen, and F. Hoffmann-La Roche Ltd. NC has nothing to disclose. LMW has participated in clinical trials with ReveraGen Biopharma, Catabasis, and Edgewise Therapeutics and has provided a consultancy role to Santhera, Catalyst, F. Hoffmann-La Roche Ltd, and PTC Therapeutics, with funds to Dr Ward’s institution.
